RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ryvu Therapeutics Stock

Ryvu Therapeutics P/E 2024

Ryvu Therapeutics P/E

-13.94

Ticker

RVU.WA

ISIN

PLSELVT00013

WKN

A1JUH2

As of Oct 28, 2024, Ryvu Therapeutics's P/E ratio was -13.94, a 0.14% change from the -13.92 P/E ratio recorded in the previous year.

The Ryvu Therapeutics P/E history

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Ryvu Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Ryvu Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Ryvu Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Ryvu Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Ryvu Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Ryvu Therapeutics stock

What is the price-to-earnings ratio of Ryvu Therapeutics?

The price-earnings ratio of Ryvu Therapeutics is currently -13.94.

How has the price-earnings ratio of Ryvu Therapeutics changed compared to last year?

The price-to-earnings ratio of Ryvu Therapeutics has increased by 0.14% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Ryvu Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Ryvu Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Ryvu Therapeutics affect the company?

An increase in the price-earnings ratio of Ryvu Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Ryvu Therapeutics affect the company?

A decrease in the price-earnings ratio of Ryvu Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Ryvu Therapeutics?

Some factors that influence the price-earnings ratio of Ryvu Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 10/28/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.